Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma

摘要

Upper gastrointestinal tract (UGI) cancers, including esophageal squamous cell carcinoma (ESCC) and gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, are the top seven most common cancers in the world.1 The incidence of ESCC and gastric cancer (GC) varies widely worldwide and the highest incidence is seen in China.2 Both of these UGI cancers have a very poor prognosis, mainly because the early symptoms of these diseases are vague and nonspecific.3, 4 Various treatment guidelines recommend combination chemotherapy as the first‐line treatment for advanced ESCC and GC.5, 6 Patients with metastatic/recurrent ESCC usually receive combination chemotherapy of cisplatin plus paclitaxel or 5‐fluorouracil.7 The chemotherapy regimen containing fluoropyrimidine and platinum is the standard regimen for patients with locally advanced/metastatic GC.8 However, the prognosis for advanced ESCC or GC patients who receive standard treatment is still unsatisfactory.